Market: Copenhagen Symbol: CHR ISIN: DK0060227585 Industry: Health Care
Chr. Hansen is a global bioscience company that develops natural solutions for the food, nutritional, pharmaceutical and agricultural industries. We develop and produce cultures, enzymes, probiotics and natural colors for a rich variety of foods, confectionery, beverages, dietary supplements and even animal feed.

Share Data 14/10/2019
Currency DKK
Previous Close 543.80
52 Weeks % -16.11
Volume 523,995
Number of Shares 131,852,496
Market Cap (bil.) 71.7
Previous Close Currency 52 Weeks % Volume Number of Shares Market Cap (bil.)
543.80 DKK -16.11 523,995 131,852,496 71.7

Key figures, EUR million
         
Income statement 2017/18 2016/17 2015/16 2014/15
Revenue 1,097.4 1,062.5 948.9 858.6
Gross profit 600.6 578.1 505.4 446.4
EBITDA before special items 384.0 368.1 324.0 286.4
EBIT before special items 320.2 307.1 267.8 232.5
EBIT 320.2 305.7 255.6 232.5
Net financial items (24.1) (14.8) (16.2) (12.8)
Profit from continuing operations 228.2 224.0 183.8 162.5
Profit for the year 228.2 224.0 183.8 162.5
Average number of employees (FTEs) 3,151 2,940 2,708 2,573
         
Financial position at August 31 2017/18 2016/17 2015/16 2014/15
Total assets 1,861.1 1,802.1 1,715.3 1,444.6
Invested capital 1,631.5 1,581.1 1,445.0 1,247.0
Net working capital 189.1 174.8 147.4 138.1
Equity 771.6 768.5 730.3 600.8
Net interest-bearing debt 658.7 628.4 547.9 487.6
         
Cash flow and investments 2017/18 2016/17 2015/16 2014/15
Cash flow from operating activities 302.4 283.7 244.8 221.5
Cash flow used for investing activities (107.0) (176.5) (244.4) (70.4)
Free cash flow 195.4 107.2 0.4 151.1
Acquisition and sale of property, plant and equipment, net (87.9) (88.4) (56.6) (55.0)
         
Earnings per share 2017/18 2016/17 2015/16 2014/15
EPS, diluted 1.73 1.68 1.40 1.23
         
Key ratios 2017/18 2016/17 2015/16 2014/15
Organic growth, % 9 10 12 10
Organic growth excl. carmine price effect, %       10
Gross margin, % 54.7 54.4 53.3 52.0
EBITDA margin before special items, % 35.0 34.6 34.1 33.4
EBIT margin before special items, % 29.2 28.9 28.2 27.1
EBIT margin, % 29.2 28.8 26.9 27.1
ROIC, % 19.9 20.3 19.9 18.9
ROIC excl. goodwill, % 38.0 40.1 39.7 37.6
NWC, % 17.2 16.5 15.5 16.1
R&D, % 7.3 7.0 7.1 6.4
Capital expenditure, % 9.8 10.0 8.2 8.2
Cash conversion, % 64.8 62.8 73.2 72.5
Net debt to EBITDA before special items 1.7x 1.7x 1.7x 1.7x